In stock and shipping daily!
Kit contains 20 tests.
Health Canada Authorization Reference Number : 323096
Rapid SARS-CoV-2 Antigen Test Card is a lateral flow immunoassay intended for the comparative detection of nucleocapsid protein from SARS-CoV-2 in NP swab specimens. Boson Rapid Antigen test has specifications of 97.46% accuracy, 93.75% sensitivity, 98.04% specificity. This device can be used by personal care services, hospitality, events, production, transportation, public sector facilities. This device is recommended for professional use. For more information, please visit the website: www.bosoncanada.com. Instructional video available here.
Please review the intended use section for more information.
High Accuracy: nasopharyngeal swab collection with clinically proven high accuracy results
Usability: three-step, cost-effective portable testing kit
Rapid Results: Compared to standard RT-PCR tests which could take multiple days for patients to receive their results, Boson Antigen testers will show results within 15–20 minutes.
Quantity: 20 tests/kit
Sample type: Nasopharyngeal swab
Storage temperature: 4–30°C
Shelf life: 18 months
Test time: 15–20 minutes (do not read results after 20 minutes)
20 Rapid SARS-CoV-2 Antigen Test Cards (Individually packaged)
2 Sample Buffer
20 Sterilized nasopharyngeal swabs (Individually packaged)
20 Extraction tubes (Individually packaged)
1 Instruction for use
1 Tube rack (for 6 tubes/rack)
Rapid SARS-CoV-2 Antigen Test Card is a lateral flow immunoassay intended for the comparative detection of nucleocapsid protein from SARS-CoV-2 in NP swab specimens. Samples are to be collected within 7 days of symptom onset by professional healthcare providers in response to individuals reporting suspected symptoms of COVID-19.
Results are for the identification of SARS-CoV-2 nucleocapsid protein. The antigen is generally detectable in nasal swab or nasopharyngeal swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of the disease.
Negative results should be treated as presumptive, do not rule out SARS-CoV-2 infection, and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management.
The Rapid SARS-CoV-2 Antigen Test Card is intended for use by trained clinical laboratory personnel specifically instructed and trained in vitro diagnostic procedures.
By purchasing this product, you agree to follow the manufacturer’s intended use and the sale conditions of this website.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.